Table 2.
Antimicrobial class/group and year | n (%) | 2016 vs 2017 |
2016 vs 2018 |
2017 vs 2018 |
|||
---|---|---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||
Amoxicillin |
1.32 (0.85–2.03) |
0.21 | 1.43 (0.94–2.20) | 0.10 | 1.10 (0.78–1.50) | 0.61 | |
2016 | 30/1093 (2.7) | ||||||
2017 | 70/1953 (3.6) | ||||||
2018 | 78/2005 (3.9) | ||||||
Amoxicillin–clavulanic acid | 1.10 (0.92–1.31) | 0.30 | 1.50 (1.26–1.79) | <0.0001 | 1.37 (1.18–1.58) | <0.0001 | |
2016 | 234/1093 (21) | ||||||
2017 | 450/1953 (23) | ||||||
2018 | 582/2005 (29) | ||||||
Fluoroquinolones | 0.85 (0.66–1.08) | 0.18 | 1.20 (0.96–1.51) | 0.11 | 1.41 (1.16–1.73) | 0.0006 | |
2016 | 122/1093 (11) | ||||||
2017 | 188/1953 (9.6) | ||||||
2018 | 263/2004 (13) | ||||||
Cefovecin | 0.91 (0.77–1.06) | 0.23 | 0.64 (0.54–0.74) | <0.0001 | 0.70 (0.62–0.80) | <0.0001 | |
2016 | 760/1093 (70) | ||||||
2017 | 1317/1953 (67) | ||||||
2018 | 1187/2005 (59) | ||||||
HP-CIA | 0.82 (0.69–0.99) | 0.034 | 0.64 (0.53–0.76) | <0.0001 | 0.77 (0.67–0.89) | 0.0005 | |
2016 | 870/1093 (80) | ||||||
2017 | 1489/1953 (76) | ||||||
2018 | 1430/2005 (71) |
OR referent is the earlier year of the comparison; OR >1 signifies an increase in prescribing of the given antimicrobial class/group in the later year (vs earlier year), while an OR <1 signifies a decrease in prescribing
HP-CIA = highest priority critically important antimicrobial